CATB Catabasis Pharmaceuticals, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

CATB [NASD]

Catabasis Pharmaceuticals, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-2.14	Insider Own	0.13%	Shs Outstand	20.08M	Perf Week	5.07%
Market Cap	29.54M	Forward P/E	-	EPS next Y	-0.86	Insider Trans	0.00%	Shs Float	20.06M	Perf Month	-75.09%
Income	-34.90M	PEG	-	EPS next Q	-0.41	Inst Own	51.00%	Short Float	3.21%	Perf Quarter	-81.05%
Sales	-	P/S	-	EPS this Y	54.10%	Inst Trans	2.73%	Short Ratio	0.54	Perf Half Y	-77.06%
Book/sh	2.54	P/B	0.57	EPS next Y	56.10%	ROA	-65.00%	Target Price	-	Perf Year	-70.77%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-73.70%	52W Range	1.25 - 8.59	Perf YTD	-75.47%
Dividend	-	P/FCF	-	EPS past 5Y	31.70%	ROI	-	52W High	-83.12%	Beta	1.98
Dividend %	-	Quick Ratio	8.00	Sales past 5Y	-	Gross Margin	-	52W Low	16.00%	ATR	0.24
Employees	27	Current Ratio	8.00	Sales Q/Q	-	Oper. Margin	-	RSI (14)	22.33	Volatility	5.13% 8.08%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	0.20%	Profit Margin	-	Rel Volume	1.86	Prev Close	1.36
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	1.18M	Price	1.45
Recom	3.00	SMA20	-8.49%	SMA50	-67.24%	SMA200	-73.55%	Volume	2,201,932	Change	6.62%

Nov-02-20

Downgrade

Wedbush

Outperform → Neutral

Oct-27-20

Downgrade

Oppenheimer

Outperform → Perform

Oct-27-20

Downgrade

H.C. Wainwright

Buy → Neutral

Oct-01-20

Initiated

H.C. Wainwright

Buy

$24

Oct-05-17

Reiterated

Oppenheimer

Outperform

$4 → $7

Feb-02-17

Downgrade

Citigroup

Buy → Neutral

Dec-22-16

Initiated

H.C. Wainwright

Buy

$14

Jun-08-16

Reiterated

Wedbush

Outperform

$27 → $17

Jul-20-15

Initiated

Wedbush

Outperform

$27

Jul-20-15

Initiated

Oppenheimer

Outperform

$28

Jul-20-15

Initiated

Citigroup

Buy

$21

Nov-12-20 04:10PM	Catabasis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides a Corporate Update Business Wire
Oct-28-20 07:41AM	The Daily Biotech Pulse: Sanofi-GlaxoSmithKline To Supply 200M Doses To COVID-19 Vaccine Alliance, Gilead Earnings, Biodesix Debuts Benzinga -8.33%
Oct-27-20 08:24AM	The Daily Biotech Pulse: Catabasis Halts Duchenne Muscular Dystrophy Study, Lilly's COVID-19 Trial Disappointment, Merck, Pfizer Earnings Benzinga -70.90%
Oct-26-20 05:00PM	Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy Business Wire -7.90%
Sep-28-20 08:00AM	Catabasis Pharmaceuticals Presents Information on Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular Dystrophy, at the Virtual 25th International Congress of the World Muscle Society Business Wire
Sep-23-20 08:00AM	Catabasis Pharmaceuticals to Present During the Virtual 25th International Congress of the World Muscle Society Business Wire
Sep-21-20 08:00AM	Catabasis Pharmaceuticals Names Noah Clauser Chief Financial Officer Business Wire
Sep-10-20 08:51AM	Is Catabasis Pharmaceuticals (NASDAQ:CATB) In A Good Position To Deliver On Growth Plans? Simply Wall St.
Sep-08-20 08:00AM	Catabasis Pharmaceuticals to Present at Upcoming Virtual Investor Conferences Business Wire +9.40%
Sep-03-20 08:41AM	Are Options Traders Betting on a Big Move in Catabasis (CATB) Stock? Zacks
Sep-02-20 08:00AM	Catabasis Pharmaceuticals to Host Virtual KOL Event on Edasalonexent and Duchenne Muscular Dystrophy Business Wire
Aug-25-20 08:38AM	Catabasis Pharmaceuticals (CATB) Surges: Stock Moves 8.6% Higher Zacks -6.71%
Aug-21-20 10:35AM	Oppenheimer Says These 2 Stocks Could Surge Over 100% From Current Levels TipRanks +12.18%
Aug-10-20 04:10PM	Catabasis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Reviews Business Progress Business Wire
Aug-05-20 08:00AM	Catabasis Pharmaceuticals to Present at Virtual 2020 Wedbush PacGrow Healthcare Conference Business Wire
Aug-04-20 08:00AM	Catabasis Pharmaceuticals and Bill & Melinda Gates Medical Research Institute to Study CAT-5571 in Drug-Sensitive and Drug-Resistant Tuberculosis Business Wire +5.57%
Jul-27-20 08:00AM	Catabasis Pharmaceuticals to Report Second Quarter 2020 Financial Results on Monday, August 10th Business Wire
Jul-15-20 08:00AM	Catabasis Pharmaceuticals to Present at Parent Project Muscular Dystrophy Virtual Annual Conference Business Wire
Jun-29-20 04:10PM	Catabasis Joins Russell 3000® Index Business Wire
Jun-15-20 08:16PM	Hedge Funds Have Never Been This Bullish On Catabasis Pharmaceuticals Inc (CATB) Insider Monkey
Jun-12-20 08:00AM	Catabasis Pharmaceuticals Names Ben Harshbarger Senior Vice President, General Counsel Business Wire +6.16%
May-12-20 04:10PM	Catabasis Pharmaceuticals Reports First Quarter 2020 Financial Results and Reviews Business Progress Business Wire
08:00AM	Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular Dystrophy Business Wire
May-07-20 09:30AM	These 3 Biotech Stocks Have Massive Upside Potential, Says Wedbush TipRanks
Apr-28-20 08:00AM	Catabasis Pharmaceuticals to Report First Quarter 2020 Financial Results on Tuesday, May 12th Business Wire
Apr-17-20 08:00AM	Catabasis Pharmaceuticals to Present at 2020 Muscular Dystrophy Association Virtual Poster Session Business Wire
Mar-27-20 03:22AM	Edited Transcript of CATB earnings conference call or presentation 10-Mar-20 12:30pm GMT Thomson Reuters StreetEvents
Mar-25-20 08:00AM	Catabasis Pharmaceuticals to Present at the Upcoming 2020 Solebury Trout Virtual Investor Conference Business Wire +5.70%
Mar-24-20 04:00PM	Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies ACCESSWIRE +12.21%
Mar-18-20 08:00AM	Catabasis Pharmaceuticals to Present During the Muscular Dystrophy Association Virtual Clinical Trials Session Business Wire -15.55%
Mar-14-20 09:32AM	If You Had Bought Catabasis Pharmaceuticals (NASDAQ:CATB) Stock Three Years Ago, You'd Be Sitting On A 76% Loss, Today Simply Wall St.
Mar-10-20 08:05AM	Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Reviews Business Progress Business Wire
06:30AM	Catabasis Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-25-20 08:00AM	Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Developments on Tuesday, March 10th Business Wire
Feb-21-20 08:00AM	Catabasis Pharmaceuticals to Present Edasalonexent at the XVIII International Conference on Duchenne and Becker Muscular Dystrophy Business Wire
Feb-03-20 04:05PM	Catabasis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Over-Allotment Option Business Wire
Jan-30-20 09:00AM	Catabasis Pharmaceuticals Announces Pricing of $23 Million Underwritten Public Offering Business Wire
Jan-29-20 04:01PM	Catabasis Pharmaceuticals Announces Proposed Underwritten Public Offering Business Wire
06:10AM	Here's Why We're Watching Catabasis Pharmaceuticals's (NASDAQ:CATB) Cash Burn Situation Simply Wall St.
Jan-09-20 04:09PM	Catabasis (CATB) Partners with UK-Based Charity for DMD Study Zacks
Jan-08-20 08:00AM	Catabasis Pharmaceuticals and Duchenne UK Announce Partnership to Evaluate Edasalonexent in a Phase 2 Non-Ambulatory Duchenne Muscular Dystrophy Trial Business Wire
Dec-24-19 06:15AM	Is Catabasis Pharmaceuticals, Inc.'s (NASDAQ:CATB) CEO Pay Fair? Simply Wall St.
Dec-23-19 02:15PM	Is Catabasis Pharmaceuticals Inc (CATB) A Good Stock To Buy? Insider Monkey +10.58%
Dec-16-19 08:00AM	Catabasis Pharmaceuticals Announces Phase 3 PolarisDMD Trial Enrolled Expected Patient Population Business Wire
Nov-25-19 06:45PM	Edited Transcript of CATB earnings conference call or presentation 7-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-18-19 06:53AM	Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB): What Does Its Beta Value Mean For Your Portfolio? Simply Wall St.
Nov-07-19 08:05AM	Catabasis Pharmaceuticals Reports Third Quarter 2019 Financial Results and Reviews Business Progress Business Wire
Oct-24-19 08:00AM	Catabasis Pharmaceuticals to Present Third Quarter 2019 Financial Results and Recent Corporate Developments on Thursday, November 7th Business Wire
Oct-19-19 09:26AM	Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB): When Will It Breakeven? Simply Wall St.
Oct-18-19 08:00AM	Catabasis Pharmaceuticals to Present at the Child Neurology Society 48th Annual Meeting Business Wire
Oct-05-19 08:00AM	Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Treatment for Duchenne Muscular Dystrophy Business Wire
Sep-30-19 04:05PM	Catabasis Pharmaceuticals Announces the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy has Exceeded Target Enrollment Business Wire
Sep-27-19 08:00AM	Catabasis Pharmaceuticals to Present the MoveDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy at the 24th International Congress of the World Muscle Society Business Wire
Sep-26-19 08:00AM	Catabasis Pharmaceuticals and the Jain Foundation Announce a Preclinical Research Collaboration to Study Edasalonexent in Dysferlinopathy Business Wire
Sep-25-19 08:00AM	Catabasis Pharmaceuticals Names Andrew A. Komjathy Chief Commercial Officer Business Wire
Sep-19-19 10:13AM	How Much Of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Do Institutions Own? Simply Wall St.
Aug-20-19 10:58AM	Investors Who Bought Catabasis Pharmaceuticals (NASDAQ:CATB) Shares Three Years Ago Are Now Down 87% Simply Wall St.
Aug-09-19 05:04PM	Edited Transcript of CATB earnings conference call or presentation 8-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Aug-08-19 08:05AM	Catabasis Pharmaceuticals Reports Second Quarter 2019 Financial Results and Reviews Business Progress Business Wire
Aug-07-19 08:00AM	Catabasis Pharmaceuticals Appoints Hugh M. Cole to its Board of Directors Business Wire
Aug-06-19 08:00AM	Catabasis Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference Business Wire
Jul-25-19 08:30AM	Catabasis Pharmaceuticals to Report Second Quarter 2019 Financial Results and Recent Corporate Developments on Thursday, August 8th Business Wire
Jul-15-19 03:08PM	Does Catabasis Pharmaceuticals, Inc.'s (NASDAQ:CATB) CEO Pay Reflect Performance? Simply Wall St.
Jun-27-19 08:00AM	Catabasis Pharmaceuticals Provides Update on Global Phase 3 PolarisDMD Trial for Edasalonexent at Parent Project Muscular Dystrophy 25th Annual Conference Business Wire
Jun-21-19 09:45AM	Catabasis Pharmaceuticals Presents Preclinical Data Showing Potential for Bone Preservation with Edasalonexent in Duchenne Muscular Dystrophy Business Wire
Jun-18-19 08:00AM	Catabasis Pharmaceuticals to Present at Upcoming Symposium on Muscle-Bone Interaction in Duchenne Muscular Dystrophy and Parent Project Muscular Dystrophy 25th Annual Conference Business Wire +6.61%
Jun-07-19 09:24AM	Vertex Expands Collaboration With CRISPR, Acquires Exonics Zacks
May-15-19 06:33PM	Edited Transcript of CATB earnings conference call or presentation 14-May-19 12:30pm GMT Thomson Reuters StreetEvents +7.46%
08:38AM	SV Life Sciences Advisers, LLC Buys Catabasis Pharmaceuticals Inc, Sells KalVista ... GuruFocus.com
May-14-19 08:05AM	Catabasis Pharmaceuticals Reports First Quarter 2019 Financial Results and Reviews Business Progress Business Wire
May-02-19 08:00AM	Catabasis Pharmaceuticals to Present Data from the MoveDMD® trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 71st Annual Meeting Business Wire
Apr-30-19 08:00AM	Catabasis Pharmaceuticals to Report First Quarter 2019 Financial Results and Recent Corporate Developments on Tuesday, May 14th Business Wire
Apr-26-19 03:26PM	Should You Be Concerned About Catabasis Pharmaceuticals, Inc.'s (NASDAQ:CATB) Historical Volatility? Simply Wall St.
Apr-12-19 11:34AM	Top Ranked Momentum Stocks to Buy for April 12th Zacks
Apr-01-19 08:00AM	Catabasis Pharmaceuticals to Present at Upcoming Neuromuscular Translational Research Conference and MDA Clinical and Scientific Conference Business Wire
Mar-26-19 12:11PM	Proteostasis Plunges on Weak Data From Cystic Fibrosis Study Zacks
08:07AM	Will Catabasis Pharmaceuticals Continue to Surge Higher? Zacks
Mar-19-19 12:26PM	Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight Zacks
Mar-18-19 09:02AM	Rising P/E an Overlooked Criterion: 5 Top Stocks Zacks +9.54%
Mar-14-19 06:09PM	Edited Transcript of CATB earnings conference call or presentation 14-Mar-19 12:30pm GMT Thomson Reuters StreetEvents
08:30AM	Catabasis (CATB) Beats Earnings in Q4, Revenues Nil Zacks
08:05AM	Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Reviews Business Progress Business Wire
Mar-13-19 08:00AM	Catabasis Pharmaceuticals to Present at Oppenheimers 29th Annual Healthcare Conference Business Wire
Mar-08-19 09:54AM	Townsquare (TSQ) to Report Q4 Earnings: What's in the Cards? Zacks +7.77%
Mar-07-19 08:57AM	Athersys (ATHX) Q4 Earnings: What's in Store for the Stock? Zacks
08:51AM	Is a Beat in Store for Catabasis (CATB) This Earnings Season? Zacks
Mar-06-19 01:56PM	Investors Who Bought Catabasis Pharmaceuticals Shares Three Years Ago Are Now Down 93% Simply Wall St.
Feb-28-19 08:00AM	Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Developments on Thursday, March 14 Business Wire
Feb-19-19 08:00AM	Catabasis Pharmaceuticals Presents Data Supporting Edasalonexent as a Potential Foundational Treatment for Duchenne Muscular Dystrophy Business Wire +6.31%
Feb-14-19 08:00AM	Catabasis Pharmaceuticals Appoints Joanne T. Beck to its Board of Directors Business Wire
Feb-06-19 09:00AM	Catabasis Pharmaceuticals Announces Pricing of $20 Million Underwritten Public Offering Business Wire -23.64%
08:23AM	The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering Benzinga
Feb-05-19 04:01PM	Catabasis Pharmaceuticals Announces Proposed Underwritten Public Offering Business Wire
Jan-29-19 07:55AM	New Research: Key Drivers of Growth for Tiffany, CarMax, Cars, RPC, Cleveland-Cliffs, and Catabasis Pharmaceuticals Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-15-19 11:10AM	Is Catabasis Pharmaceuticals, Inc.s (NASDAQ:CATB) CEO Overpaid Relative To Its Peers? Simply Wall St.
Jan-14-19 01:42AM	Catabasis Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy? Zacks
Jan-11-19 09:30AM	Is Catabasis Pharmaceuticals (CATB) Outperforming Other Medical Stocks This Year? Zacks
Jan-08-19 08:38AM	Agenus (AGEN) Surges: Stock Moves 9.4% Higher Zacks
Jan-04-19 08:00AM	Catabasis Pharmaceuticals Appoints Gregg Lapointe to its Board of Directors Business Wire +8.04%
Jan-03-19 08:08AM	Catabasis Pharmaceuticals Phase 3 PolarisDMD Clinical Trial for Edasalonexent in Duchenne Muscular Dystrophy Progress Update and Additional Trial Sites Open for Enrollment Business Wire

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience